SG Americas Securities LLC Raises Stock Position in Progyny, Inc. $PGNY

SG Americas Securities LLC boosted its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 225.3% during the 1st quarter, Holdings Channel reports. The firm owned 61,391 shares of the company’s stock after buying an additional 42,520 shares during the period. SG Americas Securities LLC’s holdings in Progyny were worth $1,042,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Royal Bank of Canada increased its stake in Progyny by 384.8% in the 1st quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock worth $291,000 after acquiring an additional 10,340 shares during the last quarter. Amundi raised its stake in Progyny by 103.8% during the first quarter. Amundi now owns 11,419 shares of the company’s stock valued at $264,000 after purchasing an additional 5,817 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Progyny by 6.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after purchasing an additional 14,297 shares in the last quarter. Invesco Ltd. lifted its position in Progyny by 37.4% during the second quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock valued at $8,342,000 after purchasing an additional 103,253 shares during the last quarter. Finally, Walleye Capital LLC lifted its position in Progyny by 6.9% during the second quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock valued at $266,000 after purchasing an additional 780 shares during the last quarter. 94.93% of the stock is currently owned by institutional investors.

Progyny Price Performance

Shares of Progyny stock opened at $30.22 on Friday. The stock’s fifty day moving average is $24.58 and its two-hundred day moving average is $22.53. The company has a market capitalization of $2.37 billion, a PE ratio of 39.25, a price-to-earnings-growth ratio of 2.67 and a beta of 1.01. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $30.33.

Progyny (NASDAQ:PGNY) last released its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.24. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The business had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.46 million. During the same period last year, the company earned $0.17 earnings per share. The business’s revenue for the quarter was down 26.4% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, research analysts anticipate that Progyny, Inc. will post 1.07 earnings per share for the current year.

Progyny announced that its Board of Directors has initiated a share repurchase plan on Tuesday, May 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to buy up to 10.3% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on PGNY shares. Citigroup restated an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. Wall Street Zen upgraded Progyny from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Zacks Research cut Progyny from a “strong-buy” rating to a “hold” rating in a research note on Friday, June 5th. Weiss Ratings raised Progyny from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, June 26th. Finally, Canaccord Genuity Group upgraded Progyny from a “hold” rating to a “buy” rating and upped their price objective for the company from $19.00 to $30.00 in a research report on Tuesday, May 19th. Eleven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Progyny has a consensus rating of “Moderate Buy” and a consensus price target of $29.92.

Insider Buying and Selling

In related news, COO Melissa B. Cummings sold 9,578 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $25.00, for a total value of $239,450.00. Following the transaction, the chief operating officer owned 73,371 shares of the company’s stock, valued at $1,834,275. This trade represents a 11.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Scott sold 7,439 shares of Progyny stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $26.39, for a total transaction of $196,315.21. Following the sale, the director owned 19,772 shares of the company’s stock, valued at $521,783.08. The trade was a 27.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 36,916 shares of company stock worth $939,875 over the last ninety days. 9.90% of the stock is owned by insiders.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.